What Is the Success Rate of Proton Therapy?

Proton therapy does not have a single success rate. Tumor control ranges from above 90 percent for certain eye cancers down to figures that look no different from conventional radiation for cancers like prostate. The meaningful question is always “success at what, and compared to what?” because for many cancers, proton therapy matches photon radiation in tumor kill while offering a different side-effect profile. That distinction matters more than a single headline number, and it shapes who actually benefits from choosing protons.

Why Success Rates Vary So Much by Cancer Type

Proton beams deposit most of their energy at a specific depth in tissue, then stop. This physical property, called the Bragg peak, allows radiation oncologists to concentrate the dose inside a tumor while delivering far less radiation to whatever lies behind it.¹ Conventional X-ray beams pass through the body, entering on one side and exiting the other, scattering radiation along the entire path. That difference matters most in tumors that sit close to sensitive structures like the brain, spinal cord, heart, or eyes. In those cases, the ability to spare normal tissue translates directly into better outcomes or fewer complications. For tumors surrounded by tissue that tolerates radiation fairly well, the advantage shrinks, and tumor control rates end up similar between protons and photons.

This is why you will see wildly different “success rates” quoted for proton therapy depending on which cancer is being discussed. The physics is the same in every case, but the clinical payoff depends on anatomy.

Eye Cancers Are the Strongest Success Story

Uveal melanoma, a cancer of the eye, is the tumor type where proton therapy has the longest and most convincing track record. Five-year local control rates consistently exceed 90 percent across decades of published data, and those numbers hold up at 10 and 15 years of follow-up.² The five-year rate at which patients keep the treated eye sits around 90 to 93 percent when smaller studies are excluded from the analysis. Even for large choroidal tumors (the kind that are hardest to treat), ten-year tumor control has been reported at roughly 88 percent, with eye retention around 70 percent at that mark.³

The reason protons work so well here is intuitive: the eye is small, the tumor is well-defined, and the surrounding structures (optic nerve, retina, lens) are exquisitely sensitive. A beam that stops precisely at the tumor’s back edge can treat the cancer while leaving much of the eye intact. No other form of external radiation can match that geometry as cleanly, which is why proton therapy for uveal melanoma is one of the few indications where almost no one debates whether protons are the better choice.

Skull Base Tumors

Chordomas and chondrosarcomas of the skull base are rare, slow-growing bone tumors that sit dangerously close to the brainstem and optic nerves. Surgery alone rarely removes them completely, and they require high radiation doses to control. Proton therapy has become a standard approach because it can deliver those high doses while keeping the brainstem exposure within survivable limits.

A systematic review of pure proton therapy for these tumors reported one-year local control of 100 percent, dropping to about 78 percent at five years and 68 percent at seven years.⁴ A separate analysis found that chondrosarcomas respond better than chordomas, with an estimated seven-year local control of about 94 percent for chondrosarcomas versus roughly 71 percent for chordomas.⁵ A broader systematic review across 511 patients noted that about 27 percent experienced recurrence, with a meaningful range of side effects from mild skin irritation up to rare but serious complications like temporal lobe injury or vision problems.⁶

These numbers reflect the reality that skull base tumors are difficult cancers regardless of how they are irradiated. Proton therapy does not make them easy to cure, but it makes aggressive treatment possible in a location where conventional radiation would likely cause unacceptable brain damage.

Head and Neck Cancers

For head and neck cancers, the evidence around proton therapy is less about boosting tumor control and more about reducing the collateral damage of treatment. Radiation to the head and neck region is notoriously punishing: it can cause severe mouth sores, difficulty swallowing, dry mouth, weight loss, and long-lasting changes in taste. A recent meta-analysis comparing proton therapy with photon-based intensity-modulated radiation therapy found that proton therapy cut the odds of several side effects roughly in half. Rates of mucositis, difficulty swallowing, fatigue, taste disturbance, pain, and weight loss were all significantly lower with protons.⁷

Patient-reported quality of life data tell a similar story. A systematic review of oropharyngeal cancer patients found that where significant differences existed, proton-treated patients consistently reported less dry mouth, better taste, better appetite, and fewer general symptoms compared to those who received photon radiation. That said, the advantage was not universal across every measurement and every time point, and in some areas like sexual function, photon-treated patients actually fared better.⁸

The question of whether fewer side effects justifies the higher cost of proton therapy has driven a shift in how clinical trials are designed. Earlier proton studies focused on showing equivalent tumor control with fewer complications. More recent phase III trials have started using overall survival as the primary endpoint, partly because improvements in toxicity alone were not enough to change insurance coverage decisions.⁹

Prostate Cancer

Prostate cancer is one of the most commonly treated conditions at proton therapy centers, and it is also where the evidence for a meaningful advantage over photon radiation is thinnest. A case-matched study found no significant differences in gastrointestinal or urinary side effects between proton beam therapy and intensity-modulated radiation therapy, whether measured during treatment or in the years after.¹⁰ An updated comparative analysis echoed this: gastrointestinal and urinary toxicity rates were statistically indistinguishable between the two approaches at six months, one year, and two years of follow-up.¹¹

This does not mean proton therapy “fails” for prostate cancer. Tumor control rates are excellent with either approach. It means the clinical benefit that makes protons shine in eye or skull base tumors does not materialize as clearly in the prostate, where modern photon techniques already do a good job sparing the bladder and rectum. For most men with localized prostate cancer, the two technologies deliver similar outcomes, which is why insurance companies often push back on covering the more expensive proton option for this disease.

Breast Cancer

For breast cancer, the appeal of proton therapy centers on the heart. Radiation for left-sided breast cancer often exposes the heart and the left anterior descending artery to scatter radiation, and even modest cardiac doses have been linked to long-term heart disease risk. Dosimetric comparisons show that proton plans reduce the mean heart dose dramatically compared to photon plans. One study found the mean heart dose dropped from about 1.6 Gy with photon IMRT to roughly 0.01 Gy with proton techniques, a reduction by a factor of more than 100.¹² An Indian cohort treated with proton therapy reported a mean heart dose under 1 Gy, and at a median follow-up of about a year, local control and overall survival were both 100 percent.¹³

There is a catch, though. A randomized Danish trial found that proton therapy caused noticeably more acute skin reactions than photon radiation: about 71 percent of proton-treated patients had moderate-to-severe dermatitis versus 20 percent with conventional radiation. The skin issues were temporary, resolving within a few weeks of treatment completion.¹⁴ So the tradeoff is real: better heart sparing in exchange for rougher skin during treatment. Whether that tradeoff matters depends heavily on the individual patient’s cardiac risk factors and the anatomy of their cancer.

Lung Cancer

Lung cancer is one of the trickiest sites for proton therapy because the tumor moves with every breath, and the surrounding lung tissue is low-density, which makes proton beam range harder to predict. Studies in non-small cell lung cancer suggest proton therapy achieves local control rates in the range of 78 to 85 percent at two years.¹⁵ A direct comparison of scanning beam proton therapy versus photon IMRT for stage III lung cancer found no significant difference in overall survival or progression-free survival. Median survival was about 42 months with protons and 31 months with photons, but the gap was not statistically significant. The rate of moderate-or-worse pneumonitis was numerically lower with protons (21 percent versus 40 percent), though that difference also did not reach significance in the study.¹⁶

For patients who also have interstitial lung disease, a condition where the lungs are already scarred and especially vulnerable to radiation, proton therapy may offer a way to treat the tumor while keeping lung toxicity manageable. One study in this high-risk group reported a median overall survival of about 1.8 years, with roughly 24 percent developing moderate-or-worse radiation pneumonitis within a year.¹⁷ That pneumonitis rate is concerning, but it may represent the best achievable result in patients who previously might not have been offered radiation at all.

Re-Irradiation for Recurrent Cancers

One area where proton therapy has carved out a growing niche is re-irradiation, meaning treating a tumor that has already been irradiated once. The challenge with giving a second course of radiation is that nearby tissues are already near their lifetime dose limits, and exceeding those limits risks serious or even fatal complications. Protons’ ability to limit dose beyond the target makes them an attractive option here.

For recurrent head and neck cancers that could not be surgically removed, proton re-irradiation achieved one-year local control of about 53 percent and one-year overall survival of roughly 73 percent in one series, with a median survival of 16 months. Severe acute toxicity was uncommon, though about 17 percent of patients experienced serious late side effects.¹⁸ A larger multi-institutional analysis of recurrent head and neck squamous cell carcinoma reported a one-year local control of about 72 percent with standard fractionation and 62 percent with a shorter “quad shot” regimen, though overall survival in the quad shot group was notably lower at about 29 percent at one year.¹⁹

Proton re-irradiation has also been used for recurrent esophageal cancer, where a multi-institutional report found six-month local control around 81 percent and one-year survival of 27 percent. Acute severe toxicity occurred in about 23 percent of patients, but no severe late toxicities were reported.²⁰ These are not cure-level numbers for most patients, but for cancers that have come back in previously irradiated territory, the ability to deliver meaningful treatment at all is a win.

Pediatric Cancers

Children represent the patient group where the theoretical advantages of proton therapy translate most clearly into long-term benefit. A child’s developing tissues are far more sensitive to radiation damage than an adult’s, and because children who survive cancer have decades of life ahead, late effects like growth impairment, hormonal problems, cognitive deficits, and second cancers matter enormously. Brain and spinal tumors are the second most common childhood malignancy, and treating them often requires irradiating large volumes of the central nervous system.²¹ Proton therapy’s ability to reduce the total dose absorbed by healthy organs makes it appealing for nearly any pediatric cancer requiring radiation. In practice, pediatric tumors represent one of the few cancer types where insurance approval for proton therapy is rarely contested.

Does Proton Therapy Lower the Risk of Second Cancers?

Because protons deposit less radiation in healthy tissue, they should, in theory, cause fewer radiation-induced second cancers. Modeling studies support this. One analysis of head and neck cancer patients estimated that photon therapy was roughly 1.8 times more likely to cause a secondary cancer than proton therapy, with the ratio varying between about 1.6 and 2.0 depending on assumptions about how protons interact with tissue at the biological level.²² Multiple dosimetric studies across various cancer types have supported a reduced risk of secondary malignancy with protons, and early clinical data are emerging in agreement, though the proton-treated populations have not yet been followed long enough for definitive confirmation.²³ This is another reason proton therapy is especially compelling for young patients, where the decades-long risk of a treatment-induced second tumor is most relevant.

Why Proton Therapy Is Harder to Deliver Than It Looks on Paper

Proton beams are more sensitive to anything that changes the distance between the skin surface and the tumor. Weight loss or gain during treatment, tumor shrinkage, bowel gas, and breathing motion can all shift where the beam stops, potentially pushing the high-dose zone off the tumor and onto healthy tissue.²⁴ Studies have found differences of more than 5 mm in the tissue thickness along the beam path between planning scans and treatment day scans, which is enough to affect dose delivery.²⁵ Conventional photon radiation is more forgiving of these shifts because the beam passes through the body regardless. Proton centers compensate by using daily imaging, breath-hold techniques, and built-in safety margins, but these uncertainties help explain why the theoretical dosimetric advantages of protons do not always translate into measurable clinical differences.

The Cost Question

Proton therapy is expensive. The machines cost hundreds of millions of dollars to build and maintain, and treatment courses typically cost more than photon-based alternatives. Whether that extra cost is worth it depends on whether proton therapy delivers meaningfully better outcomes for a given cancer type. Cost-effectiveness analyses for head and neck cancer have produced a wide range of estimates. A systematic review found that the cost per quality-adjusted life year gained ranged from roughly $4,400 to $695,000, depending on the cancer subtype, the perspective of the analysis, and the specific comparison being made.²⁶ For oropharyngeal cancer specifically, one model estimated that proton therapy added about $5,000 in total treatment costs while gaining a small improvement in quality-adjusted survival, yielding a cost per quality-adjusted life year of roughly $72,500.²⁷

Insurance coverage remains a significant barrier. A study of proton therapy referrals found that insurance category was the strongest predictor of whether initial authorization would be denied, with commercially insured adult patients facing higher denial rates than Medicaid patients.²⁸ Denials and appeals can delay the start of treatment, which for aggressive cancers is not a trivial problem. The coverage landscape is gradually expanding as more randomized trial data accumulate, but access remains uneven.

FLASH Proton Therapy and What Comes Next

The next frontier in proton therapy is called FLASH, a technique that delivers the radiation dose at ultra-high rates, orders of magnitude faster than conventional treatment. In preclinical studies, FLASH-rate proton therapy appears to reduce damage to normal tissue while maintaining the same ability to kill tumor cells.²⁹ If that finding holds up in human trials, it would represent a major leap: the normal-tissue sparing of protons combined with an additional layer of biological protection from the speed of delivery.³⁰ Clinical trials are underway, but the technology is still in its early stages and is not yet available as a standard treatment option.

Another active area of research is combining proton therapy with immunotherapy. Preclinical studies in mouse models of oral cancer have shown that radiation combined with anti-PD-L1 immunotherapy produces stronger tumor responses than either treatment alone, with effects ranging from 20 to 70 percent tumor volume reduction depending on the dose and tumor model.³¹ Whether protons or photons pair better with immunotherapy is still an open question. One colorectal cancer model found a significant survival benefit only when photon radiation was combined with immunotherapy, not protons, while other models have shown the opposite tendency.³² The biology here is genuinely complex, and researchers are still working out which radiation type triggers a stronger immune response against different tumor types. How these combinations perform in human patients will likely shape the next decade of proton therapy research.